Page last updated: 2024-11-13
zilascorb
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
zilascorb: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 54682464 |
CHEMBL ID | 2221292 |
SCHEMBL ID | 62540 |
MeSH ID | M0192335 |
Synonyms (18)
Synonym |
---|
tumor necrosisfactor-alpha (tnf-.a.) & sodium 5,6-benzylidene-l-ascorbate |
sba & tnf-.a. |
(4's,5r)-3,4-dihydroxy-5-(2'-phenyl-[1',3']dioxolan-4'-yl)-5h-furan-2-one |
(2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one |
zilascorb |
l-ascorbic acid, 5,6-o-(phenylmethylene)- |
sodium-5,6-o-benzylidene ascorbate |
5,6-o-benzylidene-l-ascorbic acid |
20664-60-2 |
t544m6z94a , |
unii-t544m6z94a |
SCHEMBL62540 |
SWTGJCNCBUCXSS-ISUZDFFFSA-N |
CHEMBL2221292 |
l-ascorbic acid, 5,6-o-benzylidene- |
DTXSID50942865 |
5,6-o-benzylidenehex-1-enofuranos-3-ulosato(2-) |
Q27289686 |
Research Excerpts
Overview
Zilascorb(2H) is a benzaldehyde derivative giving rise to strong protein synthesis inhibition.
Excerpt | Reference | Relevance |
---|---|---|
"Zilascorb(2H) is a benzaldehyde derivative giving rise to strong protein synthesis inhibition. " | ( Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma. Aamdal, S; Gullaksen, N; Ingvar, C; Mette, E; Osmundsen, K; Semb, KA, 1998) | 3.19 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Zilascorb(2H) in tablet formulation had a bioavailability of 32%, was quickly absorbed and slowly eliminated." | ( Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Aamdal, S; Bibow, K; Fodstad, O; Klem, B; Osmundsen, K; Semb, KA, 1997) | 2.65 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (85.71) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (5.41%) | 5.53% |
Reviews | 2 (5.41%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 33 (89.19%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |